A Phase 2 interventional study of Placebo to Ertugliflozin and Ertugliflozin 1 mg in Diabetes Mellitus, Type 2, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-09-13.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 5 that started in 2010, is one of 3 in phase 2, and was the 3rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Amsterdam UMC, location VUmc · Sites in United States, Netherlands
Ages 18–85
Baylor Research Institute · Sites in United States
Ages 18–84
Shanghai Zhongshan Hospital · Sites in China
Ages 19+
By country, each count listing its studies:
ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 375 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 83 across the 28 interventional studies. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 62nd largest by enrollment of the 170 interventional ones that give a count, is one of 16 that started in 2010, is one of 21 in phase 2, and was the 96th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
MK-8835-016 (B1521006) is designed to evaluate the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729) in participants with Type 2 diabetes mellitus. Participants in the study will receive 1 of 6 treatments for 12 weeks including 1 treatment with an approved drug (sitagliptin) for the treatment of Type 2 diabetes mellitus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days
Drug: Placebo to Ertugliflozin · Drug: Placebo to Sitagliptin · Drug: Metformin
Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
Drug: Placebo to Ertugliflozin · Drug: Ertugliflozin 1 mg · Drug: Placebo to Sitagliptin · Drug: Metformin
Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
Drug: Placebo to Ertugliflozin · Drug: Ertugliflozin 5 mg · Drug: Placebo to Sitagliptin · Drug: Metformin
Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days
Drug: Placebo to Ertugliflozin · Drug: Ertugliflozin 5 mg · Drug: Placebo to Sitagliptin · Drug: Metformin
Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days
Drug: Placebo to Ertugliflozin · Drug: Ertugliflozin 25 mg · Drug: Placebo to Sitagliptin · Drug: Metformin
Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days
Drug: Placebo to Ertugliflozin · Drug: Sitagliptin 100 mg · Drug: Metformin
Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
Tablet, 1 mg, once daily for 84 days
Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days
Tablet, 25 mg, once daily for 84 days
Tablet, 100 mg, once daily for 84 days
Also known as: Januvia®, Tesavel®, Xelevia®, Ristaben®
Tablet, matching placebo to 100 mg, once daily for 84 days
Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
Also known as: Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®
Baseline Hemoglobin A1c (HbA1c)
HbA1c is measured as percent.
Time frame: Baseline
Change From Baseline in HbA1c at Week 12
HbA1c is measured as percent. The change from baseline is the Week 12 HbA1c percent minus the Week 0 HbA1c percent (last observation carried forward \[LOCF\]).
Time frame: Baseline and Week 12
Change From Baseline in HbA1C at Week 2
HbA1c is measured as percent. The change from baseline is the Week 2 HbA1c percent minus the Week 0 HbA1c percent (LOCF).
Time frame: Baseline and Week 2
Change From Baseline in HbA1c at Week 4
HbA1c is measured as percent. The change from baseline is the Week 4 HbA1c percent minus the Week 0 HbA1c percent (LOCF).
Time frame: Baseline and Week 4
Change From Baseline in HbA1c at Week 8
HbA1c is measured as percent. The change from baseline is the Week 8 HbA1c percent minus the Week 0 HbA1c percent (LOCF).
Time frame: Baseline and Week 8
Baseline Body Weight
Time frame: Baseline
Percent Change From Baseline in Body Weight at Week 12
The percent change from baseline is the (\[Week 12 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).
Time frame: Baseline and Week 12
Percent Change From Baseline in Body Weight at Week 2
The percent change from baseline is the (\[Week 2 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).
Time frame: Baseline and Week 2
Percent Change From Baseline in Body Weight at Week 4
The percent change from baseline is the (\[Week 4 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).
Time frame: Baseline and Week 4
Percent Change From Baseline in Body Weight at Week 8
The percent change from baseline is the (\[Week 8 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).
Time frame: Baseline and Week 8
Baseline Systolic Blood Pressure
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.
Time frame: Baseline
Change From Baseline in Systolic Blood Pressure at Week 12
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).
Time frame: Baseline and Week 12
Change From Baseline in Systolic Blood Pressure at Week 2
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).
Time frame: Baseline and Week 2
Change From Baseline in Systolic Blood Pressure at Week 4
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).
Time frame: Baseline and Week 4
Change From Baseline in Systolic Blood Pressure at Week 8
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).
Time frame: Baseline and Week 8
Baseline Diastolic Blood Pressure
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.
Time frame: Baseline
Change From Baseline in Diastolic Blood Pressure at Week 12
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).
Time frame: Baseline and Week 12
Change From Baseline in Diastolic Blood Pressure at Week 2
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).
Time frame: Baseline and Week 2
Change From Baseline in Diastolic Blood Pressure at Week 4
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).
Time frame: Baseline and Week 4
Change From Baseline in Diastolic Blood Pressure at Week 8
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).
Time frame: Baseline and Week 8
Baseline Fasting Plasma Glucose
Laboratory measurements were performed after an overnight fast ≥8 hours in duration.
Time frame: Baseline
Change From Baseline in Fasting Plasma Glucose at Week 12
The change from baseline is the Week 12 FPG minus the Week 0 fasting plasma glucose (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.
Time frame: Baseline and Week 12
Change From Baseline in Fasting Plasma Glucose at Week 2
The change from baseline is the Week 2 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.
Time frame: Baseline and Week 2
Change From Baseline in Fasting Plasma Glucose at Week 4
The change from baseline is the Week 4 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.
Time frame: Baseline and Week 4
Change From Baseline in Fasting Plasma Glucose at Week 8
The change from baseline is the Week 8 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.
Time frame: Baseline and Week 8
Percentage of Participants Achieving HbA1c <7% at Week 12
Laboratory measurements were performed after an overnight fast ≥8 hours in duration.
Time frame: Week 12
Percentage of Participants Achieving HbA1C <6.5% at Week 12
Laboratory measurements were performed after an overnight fast ≥8 hours in duration.
Time frame: Week 12
Number of Participants Who Experienced an Advere Event (AE)
An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin.
Time frame: Up to 98 days
Number of Participants Who Discontinued Study Medication Due to an AE
An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin and excludes a temporary discontinuation of study medication.
Time frame: Up to 84 days
| Milestone | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg | Metformin Run-in |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 375 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 328 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 47 |
| Withdrew: Adverse event not related to study drug | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Did not meet entrance criteria | 0 | 0 | 0 | 0 | 0 | 0 | 14 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 13 |
| Withdrew: Other reason not specified | 0 | 0 | 0 | 0 | 0 | 0 | 7 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Milestone | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg | Metformin Run-in |
|---|---|---|---|---|---|---|---|
| Started | 54 | 54 | 55 | 55 | 55 | 55 | 0 |
| Completed | 44 | 50 | 49 | 44 | 47 | 52 | 0 |
| Not completed | 10 | 4 | 6 | 11 | 8 | 3 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 1 | 5 | 4 | 1 | 0 |
| Withdrew: Other reason not specified | 1 | 2 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Withdrew: Adverse event related to study drug | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Insufficient clinical response | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event not related to study drug | 0 | 1 | 2 | 1 | 1 | 1 | 0 |
HbA1c is measured as percent.
| Percent | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Baseline Hemoglobin A1c (HbA1c) | 8.08 ± 0.14 | 8.01 ± 0.17 | 7.88 ± 0.13 | 8.13 ± 0.17 | 8.30 ± 0.16 | 8.24 ± 0.15 |
HbA1c is measured as percent. The change from baseline is the Week 12 HbA1c percent minus the Week 0 HbA1c percent (last observation carried forward \[LOCF\]).
| Percent | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in HbA1c at Week 12 | -0.11 (-0.25 to 0.04) | -0.56 (-0.69 to -0.42) | -0.80 (-0.94 to -0.66) | -0.73 (-0.87 to -0.58) | -0.83 (-0.98 to -0.69) | -0.87 (-1.01 to -0.73) |
HbA1c is measured as percent. The change from baseline is the Week 2 HbA1c percent minus the Week 0 HbA1c percent (LOCF).
| Percent | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in HbA1C at Week 2 | 0.00 (-0.08 to 0.07) | -0.14 (-0.21 to -0.06) | -0.29 (-0.36 to -0.21) | -0.22 (-0.29 to -0.15) | -0.17 (-0.25 to -0.10) | -0.26 (-0.33 to -0.18) |
HbA1c is measured as percent. The change from baseline is the Week 4 HbA1c percent minus the Week 0 HbA1c percent (LOCF).
| Percent | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in HbA1c at Week 4 | -0.04 (-0.13 to 0.06) | -0.40 (-0.50 to -0.31) | -0.49 (-0.59 to -0.40) | -0.48 (-0.57 to -0.38) | -0.40 (-0.49 to -0.30) | -0.48 (-0.57 to -0.38) |
HbA1c is measured as percent. The change from baseline is the Week 8 HbA1c percent minus the Week 0 HbA1c percent (LOCF).
| Percent | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in HbA1c at Week 8 | -0.10 (-0.22 to -0.02) | -0.57 (-0.69 to -0.45) | -0.76 (-0.88 to -0.64) | -0.73 (-0.85 to -0.60) | -0.75 (-0.87 to -0.62) | -0.77 (-0.89 to -0.65) |
| kg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Baseline Body Weight | 83.78 ± 2.37 | 83.44 ± 2.57 | 85.74 ± 2.82 | 82.28 ± 2.93 | 81.81 ± 2.34 | 85.52 ± 2.61 |
The percent change from baseline is the (\[Week 12 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).
| Percent change | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Body Weight at Week 12 | -0.75 (-1.18 to -0.32) | -1.90 (-2.32 to -1.48) | -2.50 (-2.92 to -2.07) | -2.90 (-3.33 to -2.47) | -2.66 (-3.10 to -2.23) | -0.30 (-0.72 to 0.13) |
The percent change from baseline is the (\[Week 2 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).
| Percent change | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Body Weight at Week 2 | -0.24 (-0.46 to -0.02) | -0.65 (-0.87 to -0.44) | -1.36 (-1.59 to -1.14) | -1.14 (-1.36 to -0.92) | -1.11 (-1.33 to -0.88) | 0.21 (-0.01 to 0.43) |
The percent change from baseline is the (\[Week 4 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).
| Percent change | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Body Weight at Week 4 | -0.44 (-0.73 to -0.15) | -1.20 (-1.48 to -0.92) | -1.76 (-2.04 to -1.48) | -1.68 (-1.97 to -1.39) | -1.52 (-1.81 to -1.23) | 0.01 (-0.28 to 0.30) |
The percent change from baseline is the (\[Week 8 body weight minus the Week 0 body weight\] divided by the Week 0 body weight) X 100 (LOCF).
| Percent change | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Body Weight at Week 8 | -0.62 (-0.96 to -0.28) | -1.65 (-1.98 to -1.32) | -2.18 (-2.52 to -1.85) | -2.30 (-2.64 to -1.96) | -2.40 (-2.74 to -2.06) | -0.38 (-0.71 to -0.05) |
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Baseline Systolic Blood Pressure | 126.7 ± 1.71 | 126.5 ± 2.18 | 127.9 ± 2.31 | 125.8 ± 1.97 | 124.9 ± 2.20 | 126.6 ± 1.83 |
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure at Week 12 | -0.55 (-2.55 to 1.44) | -2.69 (-4.63 to -0.75) | -4.03 (-5.99 to -2.07) | -3.43 (-5.43 to -1.43) | -3.93 (-5.94 to -1.91) | -1.09 (-3.05 to 0.87) |
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure at Week 2 | -1.93 (-3.73 to -0.12) | -2.30 (-4.08 to -0.51) | -4.73 (-6.57 to -2.89) | -2.28 (-4.10 to -0.45) | -5.39 (-7.23 to -3.55) | -0.91 (-2.74 to 0.91) |
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure at Week 4 | -2.57 (-4.31 to -0.82) | -3.94 (-5.64 to -2.25) | -5.15 (-6.86 to -3.44) | -5.43 (-7.17 to -3.69) | -3.33 (-5.09 to -1.57) | -3.32 (-5.05 to -1.60) |
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure at Week 8 | -0.44 (-2.42 to 1.55) | -1.53 (-3.46 to 0.40) | -2.85 (-4.80 to -0.90) | -3.04 (-5.03 to -1.06) | -3.30 (-5.31 to -1.30) | -2.43 (-4.38 to -0.48) |
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Baseline Diastolic Blood Pressure | 79.14 ± 1.24 | 78.95 ± 1.14 | 78.19 ± 1.36 | 78.45 ± 1.32 | 78.61 ± 1.24 | 79.15 ± 1.01 |
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Diastolic Blood Pressure at Week 12 | 0.81 (-0.41 to 2.02) | -1.12 (-2.30 to 0.06) | -1.01 (-2.20 to 0.18) | -3.18 (-4.40 to -1.97) | -1.83 (-3.06 to -0.61) | 1.68 (0.49 to 2.87) |
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Diastolic Blood Pressure at Week 2 | -0.57 (-1.69 to 0.56) | -1.25 (-2.37 to -0.14) | -1.26 (-2.41 to -0.12) | -1.97 (-3.11 to -0.84) | -3.01 (-4.16 to -1.86) | 0.92 (-0.22 to 2.06) |
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Diastolic Blood Pressure at Week 4 | -0.80 (-1.80 to 0.21) | -2.47 (-3.44 to -1.49) | -3.08 (-4.07 to -2.10) | -2.81 (-3.81 to -1.80) | -2.10 (-3.11 to -1.09) | -0.51 (-1.51 to 0.48) |
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).
| mmHg | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Diastolic Blood Pressure at Week 8 | 0.80 (-0.40 to 1.99) | -1.40 (-2.56 to -0.24) | -0.69 (-1.86 to 0.48) | -2.23 (-3.42 to -1.04) | -1.20 (-2.40 to 0.01) | 0.32 (-0.85 to 1.49) |
Laboratory measurements were performed after an overnight fast ≥8 hours in duration.
| mg/dL | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Baseline Fasting Plasma Glucose | 165.3 ± 5.65 | 162.5 ± 6.75 | 156.5 ± 5.79 | 163.3 ± 6.30 | 171.3 ± 7.69 | 166.2 ± 6.70 |
The change from baseline is the Week 12 FPG minus the Week 0 fasting plasma glucose (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.
| mg/dL | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 12 | 2.76 (-2.47 to 8.00) | -18.23 (-23.32 to -13.14) | -23.06 (-28.21 to -17.90) | -31.47 (-36.71 to -26.24) | -29.26 (-34.58 to -23.94) | -17.29 (-22.43 to -12.15) |
The change from baseline is the Week 2 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.
| mg/dL | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 2 | 5.89 (0.50 to 11.27) | -15.07 (-20.46 to -9.69) | -15.68 (-21.19 to -10.17) | -26.65 (-32.09 to -21.21) | -16.44 (-21.97 to -10.91) | -14.69 (-20.07 to -9.30) |
The change from baseline is the Week 4 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.
| mg/dL | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 4 | 5.17 (0.10 to 10.24) | -16.91 (-21.84 to -11.99) | -22.77 (-27.77 to -17.78) | -27.95 (-33.02 to -22.88) | -26.62 (-31.77 to -21.46) | -18.00 (-22.98 to -13.03) |
The change from baseline is the Week 8 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.
| mg/dL | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 8 | 3.82 (-1.06 to 8.69) | -18.25 (-22.99 to -13.51) | -24.69 (-29.49 to -19.89) | -31.59 (-36.46 to -26.71) | -30.99 (-35.94 to -26.04) | -18.93 (-23.71 to -14.15) |
Laboratory measurements were performed after an overnight fast ≥8 hours in duration.
| Percentage of participants | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving HbA1c <7% at Week 12 | 15.6 | 44.0 | 42.9 | 38.6 | 36.2 | 43.1 |
Laboratory measurements were performed after an overnight fast ≥8 hours in duration.
| Percentage of participants | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving HbA1C <6.5% at Week 12 | 6.7 | 12.0 | 20.4 | 13.6 | 14.9 | 25.5 |
An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin.
| Participants | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg | Metformin Run-in |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced an Advere Event (AE) | 29 | 31 | 30 | 29 | 28 | 30 | 82 |
An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin and excludes a temporary discontinuation of study medication.
| Participants | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg | Metformin Run-in |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Medication Due to an AE | 1 | 1 | 3 | 2 | 1 | 1 | 3 |
Collected over Up to 24 weeks (including 10-week run-in period, 12-week treatment period, and 2-week follow-up period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/54 (0%) | 13/54 (24.1%) |
| Ertugliflozin 1 mg | — | 0/54 (0%) | 10/54 (18.5%) |
| Ertugliflozin 5 mg | — | 2/55 (3.6%) | 14/55 (25.5%) |
| Ertugliflozin 10 mg | — | 0/55 (0%) | 14/55 (25.5%) |
| Ertugliflozin 25 mg | — | 1/55 (1.8%) | 10/55 (18.2%) |
| Sitagliptin 100 mg | — | 1/55 (1.8%) | 12/55 (21.8%) |
| Metformin Run-in | — | 2/375 (0.5%) | 30/375 (8%) |
| Event | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg | Metformin Run-in |
|---|---|---|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/54 | 0/54 | 1/55 | 0/55 | 1/55 | 0/55 | 0/375 |
| CellulitisInfections and infestations | 0/54 | 0/54 | 1/55 | 0/55 | 0/55 | 0/55 | 0/375 |
| SyncopeVascular disorders | 0/54 | 0/54 | 1/55 | 0/55 | 0/55 | 0/55 | 0/375 |
| Coronary artery stenosisCardiac disorders | 0/54 | 0/54 | 0/55 | 0/55 | 0/55 | 1/55 | 0/375 |
| Food allergyImmune system disorders | 0/54 | 0/54 | 0/55 | 0/55 | 0/55 | 0/55 | 1/375 |
| Myocardial infarctionCardiac disorders | 0/54 | 0/54 | 0/55 | 0/55 | 0/55 | 0/55 | 1/375 |
| Event | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg | Metformin Run-in |
|---|---|---|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/54 | 2/54 | 6/55 | 2/55 | 2/55 | 0/55 | 4/375 |
| Urinary tract infectionInfections and infestations | 4/54 | 2/54 | 0/55 | 5/55 | 0/55 | 1/55 | 4/375 |
| DiarrhoeaGastrointestinal disorders | 1/54 | 2/54 | 1/55 | 2/55 | 3/55 | 4/55 | 14/375 |
| Genital infection fungalInfections and infestations | 1/54 | 0/54 | 1/55 | 3/55 | 4/55 | 0/55 | 2/375 |
| HeadacheNervous system disorders | 2/54 | 1/54 | 4/55 | 1/55 | 1/55 | 1/55 | 4/375 |
| Upper respiratory tract infectionInfections and infestations | 2/54 | 2/54 | 2/55 | 3/55 | 3/55 | 2/55 | 1/375 |
| Blood pressure increasedInvestigations | 2/54 | 1/54 | 1/55 | 0/55 | 1/55 | 3/55 | 0/375 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/54 | 0/54 | 3/55 | 1/55 | 1/55 | 0/55 | 5/375 |
| DizzinessNervous system disorders | 0/54 | 0/54 | 0/55 | 1/55 | 0/55 | 3/55 | 1/375 |
Of the 375 enrolled participants included in the metformin run-in period, 328 participants were randomized to 1 of 6 treatment groups.
| Age, Customized(Participants) | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg | Total |
|---|---|---|---|---|---|---|---|
| < 18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18-44 years | 8 | 10 | 6 | 1 | 9 | 13 | 47 |
| 45-64 years | 41 | 36 | 42 | 47 | 39 | 33 | 238 |
| >= 65 years | 5 | 8 | 7 | 7 | 7 | 9 | 43 |
| Sex: Female, Male(Participants) | Placebo | Ertugliflozin 1 mg | Ertugliflozin 5 mg | Ertugliflozin 10 mg | Ertugliflozin 25 mg | Sitagliptin 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 24 | 20 | 14 | 24 | 18 | 15 | 115 |
| Male | 30 | 34 | 41 | 31 | 37 | 40 | 213 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2010 to primary completion in Jan 2011, 10 months.
Results were first posted in Oct 2017, 6 years 8 months after primary completion. A results delay was requested in Nov 2012.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 10 months is below that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertugliflozin